Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 9/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 5/20 | 0.34 |
| ▸ | KRAS | P01116 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.31 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.31 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25817208 | 0.88 | CHRM4 (0.41) | CHRM4CHRM1CHRM2CHRM5ACACB | |
| SCHEMBL26780979 | 0.87 | CHRM4 (0.40) | CHRM4CHRM1 | |
| SCHEMBL25817152 | 0.85 | CHRM4 (0.41) | CHRM4CHRM1CHRM2CHRM5ACACB | |
| SCHEMBL25817192 | 0.82 | CHRM4 (0.47) | CHRM4CHRM1CHRM2CHRM5ACACB | |
| SCHEMBL23228633 | 0.81 | CHRM4 (0.46) | CHRM4CHRM1CHRM2CHRM5RORC | |
| SCHEMBL25817141 | 0.81 | CHRM4 (0.46) | CHRM4CHRM1CHRM2CHRM5ACACB | |
| SCHEMBL25817153 | 0.80 | CHRM4 (0.45) | CHRM4CHRM1CHRM2CHRM5ACACB | |
| SCHEMBL25817155 | 0.77 | CHRM4 (0.45) | CHRM4CHRM1CHRM2CHRM5ACACB | |
| SCHEMBL25817205 | 0.77 | CHRM4 (0.43) | CHRM4CHRM1CHRM2CHRM5ACACB | |
| SCHEMBL26780982 | 0.76 | CHRM4 (0.41) | CHRM4CHRM1CHRM2CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212139-A1 | 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212139-A1 | 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | CHRM2, CHRM1, CHRM3 | CHRM4 4/4885CHRM1 2/4885CHRM2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.